Cas:65399-02-2 7-methyl-2,3-dihydroisoindol-1-one manufacturer & supplier

We serve Chemical Name:7-methyl-2,3-dihydroisoindol-1-one CAS:65399-02-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

7-methyl-2,3-dihydroisoindol-1-one

Chemical Name:7-methyl-2,3-dihydroisoindol-1-one
CAS.NO:65399-02-2
Synonyms:7-METHYL-2,3-DIHYDROISOINDOLE-1-ONE;7-Methylisoindolin-1-on;7-Methylisoindolinone;7-methylisoindolin-1-one;7-methyl-2,3-dihydro-isoindol-1-one
Molecular Formula:C9H9NO
Molecular Weight:147.17400
HS Code:2933790090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:32.59000
Exact Mass:147.06800
LogP:1.24880

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-METHYL-2,3-DIHYDROISOINDOLE-1-ONE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-methyl-2,3-dihydro-isoindol-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-methylisoindolin-1-one Use and application,7-Methylisoindolin-1-on technical grade,usp/ep/jp grade.


Related News: The insulin-only and bihormonal configurations may be helpful in diabetes. 7-methyl-2,3-dihydroisoindol-1-one manufacturer The insulin-only and bihormonal configurations may be helpful in diabetes. 7-methyl-2,3-dihydroisoindol-1-one supplier “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” 7-methyl-2,3-dihydroisoindol-1-one vendor “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” 7-methyl-2,3-dihydroisoindol-1-one factory “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.”